These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2144379)

  • 1. A radioimmunoassay for SQ 27,519, the active phosphinic acid-carboxylic diacid of the prodrug fosinopril in human serum.
    Tu JI; Brennan J; Stouffer B; Eckelman WC
    Ther Drug Monit; 1990 Jul; 12(4):404-10. PubMed ID: 2144379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunoassay for ceronapril, a new angiotensin-converting enzyme inhibitor, and its application to a pharmacokinetic study in healthy male volunteers.
    Tu JI; Brennan J; Stouffer B; Mantha S; Turabi N; Tsay HM
    Ther Drug Monit; 1992 Jun; 14(3):209-19. PubMed ID: 1412607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunoassay for hydroxyphosphinyl-3-hydroxybutanoic acid (SQ 33,600), a hypocholesterolemia agent.
    Jagoda E; Stouffer B; Ogan M; Tsay HM; Turabi N; Mantha S; Yost F; Tu JI
    Ther Drug Monit; 1993 Jun; 15(3):213-9. PubMed ID: 8333001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition of fosinopril sodium in healthy subjects.
    Singhvi SM; Duchin KL; Morrison RA; Willard DA; Everett DW; Frantz M
    Br J Clin Pharmacol; 1988 Jan; 25(1):9-15. PubMed ID: 2967089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: in vitro and preclinical in vivo pharmacology.
    DeForrest JM; Waldron TL; Harvey C; Scalese B; Rubin B; Powell JR; Petrillo EW; Cushman DW
    J Cardiovasc Pharmacol; 1989 Nov; 14(5):730-6. PubMed ID: 2481187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects.
    Duchin KL; Waclawski AP; Tu JI; Manning J; Frantz M; Willard DA
    J Clin Pharmacol; 1991 Jan; 31(1):58-64. PubMed ID: 1646240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of fosinopril in patients with various degrees of renal function.
    Hui KK; Duchin KL; Kripalani KJ; Chan D; Kramer PK; Yanagawa N
    Clin Pharmacol Ther; 1991 Apr; 49(4):457-67. PubMed ID: 1826651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A radioimmunoassay for the angiotensin converting enzyme inhibitor ramipril and its active metabolite.
    Eckert HG; Münscher G; Oekonomopulos R; Strecker H; Urbach H; Wissmann H
    Arzneimittelforschung; 1985; 35(8):1251-6. PubMed ID: 3000393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative contribution of the gut, liver, and lung to the first-pass hydrolysis (bioactivation) of orally administered 14C-fosinopril sodium in dogs. In vivo and in vitro studies.
    Morrison RA; Singhvi SM; Peterson AE; Pocetti DA; Migdalof BH
    Drug Metab Dispos; 1990; 18(2):253-7. PubMed ID: 1971582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of SQ 27,519, the active phosphinic acid-carboxylic acid of the prodrug SQ 28,555, in human serum by capillary gas chromatography with nitrogen-phosphorus detection after a two-step derivatization.
    Jemal M; Ivashkiv E; Ribick M; Cohen AI
    J Chromatogr; 1985 Dec; 345(2):299-307. PubMed ID: 2935551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).
    Cushman DW; Wang FL; Fung WC; Grover GJ; Harvey CM; Scalese RJ; Mitch SL; DeForrest JM
    Br J Clin Pharmacol; 1989; 28 Suppl 2(Suppl 2):115S-130S; discussion 130S-131S. PubMed ID: 2557876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A radioimmunoassay for total captopril in human serum or plasma samples.
    Tu J; Liu E; Nickoloff EL
    Ther Drug Monit; 1984; 6(1):59-65. PubMed ID: 6369644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency.
    Sica DA; Cutler RE; Parmer RJ; Ford NF
    Clin Pharmacokinet; 1991 May; 20(5):420-7. PubMed ID: 1652404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid chromatographic-electrospray tandem mass spectrometric method for the simultaneous quantitation of the prodrug fosinopril and the active drug fosinoprilat in human serum.
    Jemal M; Mulvana DE
    J Chromatogr B Biomed Sci Appl; 2000 Mar; 739(2):255-71. PubMed ID: 10755370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme.
    Seymour AA; Swerdel JN; Abboa-Offei B
    J Cardiovasc Pharmacol; 1991 Mar; 17(3):456-65. PubMed ID: 1711608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new radioimmunoassay for the determination of the angiotensin-converting enzyme inhibitor perindopril and its active metabolite in plasma and urine: advantages of a lysine derivative as immunogen to improve the assay specificity.
    van den Berg H; Resplandy G; de Bie AT; Floor W; Bertrand M; Arts CJ
    J Pharm Biomed Anal; 1991; 9(7):517-24. PubMed ID: 1817672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension.
    Murdoch D; McTavish D
    Drugs; 1992 Jan; 43(1):123-40. PubMed ID: 1372856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril.
    Friedman DI; Amidon GL
    Pharm Res; 1989 Dec; 6(12):1043-7. PubMed ID: 2560181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of the newer ACE inhibitors. A review.
    Kelly JG; O'Malley K
    Clin Pharmacokinet; 1990 Sep; 19(3):177-96. PubMed ID: 2203579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection.
    Grover GJ; Sleph PG; Dzwonczyk S; Wang P; Fung W; Tobias D; Cushman DW
    J Pharmacol Exp Ther; 1991 Jun; 257(3):919-29. PubMed ID: 1646329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.